204 related articles for article (PubMed ID: 35535398)
1. Differential Neutralization of Unfractionated Heparin and Enoxaparin by Andexanet Alfa.
Lewis J; Iqbal O; Jeske W; Hoppensteadt D; Siddiqui F; Fareed J
Clin Appl Thromb Hemost; 2022; 28():10760296221099934. PubMed ID: 35535398
[TBL] [Abstract][Full Text] [Related]
2. Assay-Based Differentiation in the Neutralization Profile of Unfractionated Heparin, Enoxaparin, and Fondaparinux by Andexanet Alfa.
Siddiqui F; Tafur A; Bontekoe E; Iqbal O; Jeske W; Mehrotra S; Hoppensteadt D; Ramacciotti E; Fareed J
Clin Appl Thromb Hemost; 2020; 26():1076029619895120. PubMed ID: 31914798
[TBL] [Abstract][Full Text] [Related]
3. Andexanet Alfa Neutralizes the Anticoagulant Effects of Unfractionated Heparin of Bovine, Ovine and Porcine Origin Almost as Protamine Sulfate.
Siddiqui F; Hoppensteadt D; Jeske W; Ramacciotti E; Tafur A; Fareed J
Clin Appl Thromb Hemost; 2024; 30():10760296241247558. PubMed ID: 38656136
[TBL] [Abstract][Full Text] [Related]
4. Comparison of reversal activity and mechanism of action of UHRA, andexanet, and PER977 on heparin and oral FXa inhibitors.
Kalathottukaren MT; Creagh AL; Abbina S; Lu G; Karbarz MJ; Pandey A; Conley PB; Kizhakkedathu JN; Haynes C
Blood Adv; 2018 Aug; 2(16):2104-2114. PubMed ID: 30135185
[TBL] [Abstract][Full Text] [Related]
5. In vivo neutralization of unfractionated heparin and low-molecular-weight heparin by a novel salicylamide derivative.
Kuziej J; Litinas E; Hoppensteadt DA; Liu D; Walenga JM; Fareed J; Jeske W
Clin Appl Thromb Hemost; 2010 Aug; 16(4):377-86. PubMed ID: 20460347
[TBL] [Abstract][Full Text] [Related]
6. Novel concatameric heparin-binding peptides reverse heparin and low-molecular-weight heparin anticoagulant activities in patient plasma in vitro and in rats in vivo.
Schick BP; Maslow D; Moshinski A; San Antonio JD
Blood; 2004 Feb; 103(4):1356-63. PubMed ID: 14576044
[TBL] [Abstract][Full Text] [Related]
7. The effects of unfractionated heparin, low molecular weight heparin and danaparoid on the thromboelastogram (TEG): an in-vitro comparison of standard and heparinase-modified TEGs with conventional coagulation assays.
Coppell JA; Thalheimer U; Zambruni A; Triantos CK; Riddell AF; Burroughs AK; Perry DJ
Blood Coagul Fibrinolysis; 2006 Mar; 17(2):97-104. PubMed ID: 16479191
[TBL] [Abstract][Full Text] [Related]
8. Andexanet Alfa, the Possible Alternative to Protamine for Reversal of Unfractionated Heparin.
Maneno JN; Ness GL
Ann Pharmacother; 2021 Feb; 55(2):261-264. PubMed ID: 32667214
[TBL] [Abstract][Full Text] [Related]
9. Thrombin generation assays are superior to traditional tests in assessing anticoagulation reversal in vitro.
Gatt A; van Veen JJ; Woolley AM; Kitchen S; Cooper P; Makris M
Thromb Haemost; 2008 Aug; 100(2):350-5. PubMed ID: 18690358
[TBL] [Abstract][Full Text] [Related]
10. Studies on the neutralizing effects of protamine on unfractionated and low molecular weight heparin (Fragmin) at the site of activation of the coagulation system in man.
Wolzt M; Weltermann A; Nieszpaur-Los M; Schneider B; Fassolt A; Lechner K; Eichler HG; Kyrle PA
Thromb Haemost; 1995 Mar; 73(3):439-43. PubMed ID: 7667826
[TBL] [Abstract][Full Text] [Related]
11. Preparation and evaluation a new generation of low molecular weight heparin.
Zhao D; Sang Q; Cui H
Biomed Pharmacother; 2016 Apr; 79():194-200. PubMed ID: 27044828
[TBL] [Abstract][Full Text] [Related]
12. Protamine Sulfate Neutralization Profile of Various Dosages of Bovine, Ovine and Porcine UFHs and Their Depolymerized Derivatives in Non-Human Primates.
Kouta A; Jeske W; Cera L; Farshid A; Duff R; Hoppensteadt D; Fareed J
Clin Appl Thromb Hemost; 2021; 27():10760296211005544. PubMed ID: 33926250
[TBL] [Abstract][Full Text] [Related]
13. Anticoagulant mechanisms of covalent antithrombin-heparin investigated by thrombelastography. Comparison with unfractionated heparin and low-molecular-weight heparin.
Atkinson HM; Mewhort-Buist TA; Berry LR; Chan AK
Thromb Haemost; 2009 Jul; 102(1):62-8. PubMed ID: 19572069
[TBL] [Abstract][Full Text] [Related]
14. Heparin and low-molecular-weight heparin: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy.
Hirsh J; Raschke R
Chest; 2004 Sep; 126(3 Suppl):188S-203S. PubMed ID: 15383472
[TBL] [Abstract][Full Text] [Related]
15. Anticoagulant effects of low-molecular-weight heparins in healthy cats.
Alwood AJ; Downend AB; Brooks MB; Slensky KA; Fox JA; Simpson SA; Waddell LS; Baumgardner JE; Otto CM
J Vet Intern Med; 2007; 21(3):378-87. PubMed ID: 17552440
[TBL] [Abstract][Full Text] [Related]
16. Relative neutralization of the biological actions of sulfaminoheparosans (K5 derivatives) and heparins by protamine sulfate.
Maddineni J; Hoppensteadt DA; Cornelli U; Manoni M; Fareed J
Clin Appl Thromb Hemost; 2007 Jan; 13(1):52-64. PubMed ID: 17164496
[TBL] [Abstract][Full Text] [Related]
17. Low molecular weight heparin and haemodialysis: neutralization by protaminchloride.
Andrassy K
Blood Coagul Fibrinolysis; 1993 Dec; 4 Suppl 1():S39-43. PubMed ID: 8180328
[TBL] [Abstract][Full Text] [Related]
18. Effect of nonspecific binding to plasma proteins on the antithrombin activities of unfractionated heparin, low-molecular-weight heparin, and dermatan sulfate.
Cosmi B; Fredenburgh JC; Rischke J; Hirsh J; Young E; Weitz JI
Circulation; 1997 Jan; 95(1):118-24. PubMed ID: 8994426
[TBL] [Abstract][Full Text] [Related]
19. Intraoperative Unfractionated Heparin Unresponsiveness during Endovascular Repair of a Ruptured Abdominal Aortic Aneurysm following Administration of Andexanet Alfa for the Reversal of Rivaroxaban.
Eche IM; Elsamadisi P; Wex N; Wyers MC; Brat GA; Cunningham K; Bauer KA
Pharmacotherapy; 2019 Aug; 39(8):861-865. PubMed ID: 31251821
[TBL] [Abstract][Full Text] [Related]
20. Effects of unfractionated heparin, low-molecular-weight heparin, and heparinoid on thromboelastographic assay of blood coagulation.
Zmuda K; Neofotistos D; Ts'ao CH
Am J Clin Pathol; 2000 May; 113(5):725-31. PubMed ID: 10800406
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]